在轻微缺血性中风或高风险过渡性缺血性发作时,用克洛皮多格雷尔与印多布芬或阿司匹林一起服用:一项随机对照临床研究
Xudong Liu1, Xuxian Lv1, Yanfang Peng1
1The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
BMC neurology
|March 1, 2024
概括
与阿司匹林和克洛皮多格勒相比,在轻微的缺血性中风和高风险的TIA患者中,与克洛皮多格勒结合的Indobufen显示出更高的安全性和有效性. 这种新的双重抗血小板疗法显著减少了不良事件并改善了患者的治疗结果.
科学领域:
- 心血管医学 心血管医学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺血性中风和暂时缺血性发作 (TIA) 是主要的脑血管疾病.
- 传统的抗血小板疗法带有出血风险.
- 印多布芬为抗血小板聚合提供了一种潜在的比阿司匹林更安全的替代品.
研究的目的:
- 评估印多布芬加克洛皮多格勒与阿司匹林加克洛皮多格勒的有效性和安全性.
- 为了比较轻度缺血性中风或高风险TIA的患者的双重抗血小板治疗方案.
主要方法:
- 一个开放标签,随机对照试验 (CARMIA研究).
- 182名轻度缺血性中风/TIA患者被随机分配给因多布芬或阿司匹林,两者与克洛皮多格雷尔结合.
- 主要终点包括复发性缺血事件,修改的兰金尺度 (mRS),国家卫生研究院中风尺度 (NIHSS) 评分和出血事件.
主要成果:
- 印度布芬组中没有发生终点事件 (中风复发,心脏病发作,死亡),而阿司匹林组中为6.5% (P=0.029).
- 印多布芬加克洛皮多格勒的mRS得分显著降低 (P<0.0001) 并且降低了出血事件 (1.1%与8.6%,P=0.035).
- 虽然NIHSS得分的改善在数值上更高,但在统计学上并不显著.
结论:
- 印多布芬和克洛皮多格雷尔的联合治疗在有效性和安全性方面不逊色,而且可能优越.
- 这种疗法为阿司匹林加克洛皮多格雷尔治疗轻度缺血性中风和高风险的TIA提供了一个有希望的替代方案.
- 卡米亚研究提供了一个更安全的双重抗血小板策略在脑血管疾病的证据.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
512
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
512


